China’s Surgical Robotics Market, 100 Billion Winds Rise Again
China has created multiple global “firsts” in the field of robotic remote surgery. China has completed the world’s first remote robotic surgery, the world’s farthest robotic surgery, and the world’s first remote micrometer level ophthalmic surgery.
According to Frost & Sullivan, China’s surgical robot market will grow at 37%, much higher than the global 23%; It is expected to exceed 70.9 billion yuan by 2030.
According to Frost & Sullivan, China’s surgical robot market will grow at 37%, much higher than the global 23%; It is expected to exceed 70.9 billion yuan by 2030.
New product approvals reach new highs
Patients can enjoy robotic surgery for 6,000 yuan
If 2022 was the first year of China’s surgical robot business, then 2023 may be the first year of the “outbreak”.
In Shanghai, for example, as long as the robot surgery is done, no matter the degree of difficulty, no matter the length of time, it will charge 30,000 yuan. Because it is included in the scope of Shanghai healthcare payment, the self-payment ratio is 20%; Eligible patients only need to pay 6,000 yuan, and the rest is included in the healthcare payment pool.y
In 2022, more than 15 surgical robots were approved (higher than the total number approved in the previous five years), while as of October 2023, more than 19 have been approved; Domestic products account for over 80% of the total.
In China, from the stock market, the subdivision track is almost occupied by endoscopy/soft tissue robots (75%) and orthopedic robots (10%); and from the incremental market, orthopedic and natural cavity surgery robots will lead the market expansion with a growth rate of more than 50% and nearly 90%. Orthopaedical surgical robots may be the most commercially promising surgical robot track in the Chinese market in the next five years. The demand for “cost reduction and efficiency increase” after centralized procurement of orthopedic consumables and the absence of quota policy restrictions are the direct reasons for its growth rate being much higher than that of the cavity mirror track.
Up to now, more than 20 orthopedic surgical robots have been approved in China, accounting for more than 69% of domestic; In the past three years, product innovation in this field has exploded, with more than 18 products “certified” listed, many of which are the latest products of the world’s TOP enterprises.
Domestic orthopeedics robots, such as Precision’s Arthrobot multi-application joint replacement robot for hip and knee, are also said to achieve “one-click replacement” for hip and knee surgery. In addition to zero-gravity operation and precise force feedback, “open and compatible” is its biggest advantage, which can match multiple domestic and foreign brands of implants. In addition, Great Robotics’ “Newton” robot is the world’s first master-slave orthopedic endoscopic total surgery robot. Different from the “semi-process assistance” of most of the nail-setting navigation surgical robots on the market, “Newton” is the first to realize the “full process assistance” of minimally invasive orthopedic surgery. The “force feedback” function of its first control console operating handle can give real tactile feedback to doctors in real time to avoid accidental injury to patients. The natural lumen surgical robot is the fastest growing surgical robot segment due to the advantages of no wound and safer.
In September 2023, Johnson & Johnson’s Monarch robot was approved for listing in China, marking the first successful listing of a natural cavity robot in China. In addition, IntuitiveFosun’s (homegrown)Ion robot has entered the innovation green channel.
In the field of soft tissue/endoscopic surgical robots, in addition to the Da Vinci surgical robot, the listing of the first domestic single-hole robot brings more cost-effective options for patients.
As the world’s first commercial surgical robot, Da Vinci is not only a legend but also a benchmark. However, because of its porous structure, movement and rotation on the abdominal wall, it has certain limitations in execution and has been criticized clinically.
Many years ago, relevant clinical experts proposed the concept of “single-hole laparoscopic minimally invasive surgery”, that is, only a skin incision (usually the navel) is used, and all surgical instruments are entered into the patient’s abdominal cavity through the sheath tube on this skin incision to complete all surgical steps.
Under the “single-hole robot trend”, Da Vinci is also constantly iterating, and launched the SP system in 2018, which is previously the world’s first and only approved single-hole endoscopic surgery robot.
In June 2023, Shurui single hole endoscopic surgery robot was approved in China, becoming the first endoscopic single hole surgery system sold in China and the second in the world. At the same time, it is also the first serpentine arm single-hole endoscopic surgery robot in the world to start the commercialization process and be approved for market.
The advantage of a serpentine arm is its high design flexibility, which is conducive to deep stitching and knotting; And the formed “surgical operation triangle” can solve the chopstick effect of traditional single hole surgery, while also achieving a large range of surgical area coverage.
Frost & Sullivan estimates that China’s single-hole robot market will reach 15.36 billion yuan in 2030, with a growth rate of 92.2%.
Looking at other surgical robot segments (nerve, oral, panvascular, percutaneous puncture), more than 23 products have been approved.
Among them, the pan-vascular intervention field has not yet seen any giants in the world. Perhaps it is precisely because the landscape is not yet settled that new giants are more likely to emerge.
Although Siemens Healthcare announced in May this year that it was withdrawing from its Corindus Corpath business in the field of cardiovascular intervention globally, and will focus on the development of neurological intervention in the future; There is still a steady stream of entrants into the Chinese market.Approved products include VAS HERO, the first panvascular interventional robot launched in the Chinese market, which is also the world’s first whole brain arteriography surgical robot, and the first millimeter-level operation to complete all cerebrovascular interventional surgery in the doctor’s compartment.
5G gives unlimited space
In the future, the biggest market is in China?
Much of the bright future of surgical robotics comes from “remote surgery.”
After the first generation of open surgery (from the early 19th century to the present), the second generation of traditional minimally invasive surgery MIS (from the 1980s to the present), and the third generation of robotic surgery RAS (from 2000 to the present), surgery may be about to enter the era of remote precision surgery, and surgical robots are important “assistants”.
At present, the world’s first remote robotic surgery, the world’s longest distance robotic surgery, the world’s first remote micron eye surgery, etc., are all completed in China.
5G technology combined with a huge population base and vast territory may make China the largest market for surgical robots.
For remote surgery, the “time difference” is the deadliest, or will cause great deformation of stitches, excision and other actions. With the maturity of 5G technology, objectively this problem has been solved.
In practice, foreign-funded surgical robots represented by Da Vinci will still be “absent” from this revolutionary event, the biggest reason is the high 5G communication cost and low coverage in North America, Europe and other overseas countries.
According to the latest data from the Ministry of Industry and Information Technology, as of the end of April 2023, the total number of 5G base stations in the country reached 2.733 million, covering all prefecture-level cities and county cities in China, and the network scale is the first in the world.
Up to now, China Telecom and the domestic surgical robot joint, including Zhejiang University Run Run Shaw Hospital, Jiangsu Province People’s Hospital, the First Affiliated Hospital of Zhengzhou University for dozens of hospitals at all levels of Xinjiang, Tibet, Gansu, Inner Mongolia and other regions based on 5G slice private network protection of remote surgery.
The tuyere has arrived, and the global competitive pattern has accelerated its entry
In 2023, China’s surgical robot market will usher in a commercial explosion.
Taking Tinavi and Intuitive Surgery as an example, Tinavi has achieved triple-digit revenue growth for the first time since it was commercialized 7 years ago. The Q3 revenue in 2023 was 51.75 million yuan, an increase of 121.92%, and the operation volume increased by more than 70%. In the first nine months of 2023, TiRobot II performed more than 16,000 surgeries, an increase of more than 70% over the same period last year. Significantly exceeding the company’s annual surgical robot volume of 12,000 operations in 2022.
Intuitive Surgery also said in the latest financial report that the growth rate of the Chinese market reached 19% in Q3, and achieved the “localization” of two blockbuster products.
In addition, as of the first half of 2023, the Kings of various segments of the global surgical robot have gathered in the Chinese market, including:
- Endoscopy (soft tissue) : Da Vinci robot for intuitive surgery;
- Orthopaedics: Medtronic, Gemma, Stryker, Smith & Nephew;
■Through natural cavity: Johnson’s Monarch, intuitive surgery’s Ion;
According to Frost & Sullivan, China’s surgical robot market will grow at 37%, much higher than the global 23%; It is expected to exceed 70.9 billion yuan by 2030.
China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
Article Source：更多资讯
Data Source：Med Trend
Translated & edited ： Bradyknow
